Joseph W. Polli
Preclinical Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Inc,
P.O. Box 13398, Room: N1.407, Research Triangle Park, NC 27709
Tanzania
Research Article
Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes
Author(s): Joseph W. Polli, Joan E. Humphreys, Kelly A. Harmon, Lindsey O. Webster, Mindy J. Reese and Christopher C. MacLauchlinJoseph W. Polli, Joan E. Humphreys, Kelly A. Harmon, Lindsey O. Webster, Mindy J. Reese and Christopher C. MacLauchlin
